StreetInsider.com News Articles

Form 4 Oruka Therapeutics, Inc. For: Jul 15 Filed by: Goncalves Joana

Wed, 15 Jul 2026 19:36:00 -0400

si-local-file:///var/storage/secattach/20260715/26775208.html

Form 4 Oruka Therapeutics, Inc. For: Jul 15 Filed by: Goncalves Joana

Wed, 15 Jul 2026 19:36:00 -0400

si-local-file:///var/storage/secattach/20260715/26775208.html

Form 144 Oruka Therapeutics, Inc. Filed by: Goncalves Joana

Wed, 15 Jul 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260715/26774537.html

Form 144 Oruka Therapeutics, Inc. Filed by: Goncalves Joana

Wed, 15 Jul 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260715/26774537.html

Form 4 Oruka Therapeutics, Inc. For: Jul 13 Filed by: Agarwal Arjun

Mon, 13 Jul 2026 17:09:00 -0400

si-local-file:///var/storage/secattach/20260713/26763185.html

Form 4 Oruka Therapeutics, Inc. For: Jul 13 Filed by: Agarwal Arjun

Mon, 13 Jul 2026 17:09:00 -0400

si-local-file:///var/storage/secattach/20260713/26763185.html

Form 144 Oruka Therapeutics, Inc. Filed by: Agarwal Arjun

Mon, 13 Jul 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260713/26762907.html

Form 144 Oruka Therapeutics, Inc. Filed by: Agarwal Arjun

Mon, 13 Jul 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260713/26762907.html

Form 144 Oruka Therapeutics, Inc. Filed by: Fairmount Funds Management LLC

Wed, 01 Jul 2026 21:31:00 -0400

si-local-file:///var/storage/secattach/20260701/26722789.html

Form 144 Oruka Therapeutics, Inc. Filed by: Fairmount Funds Management LLC

Wed, 01 Jul 2026 21:31:00 -0400

si-local-file:///var/storage/secattach/20260701/26722789.html

Form SCHEDULE 13D/A Oruka Therapeutics, Inc. Filed by: Fairmount Funds Management LLC

Wed, 01 Jul 2026 21:30:00 -0400

si-local-file:///var/storage/secattach/20260701/26722785.html

Form SCHEDULE 13D/A Oruka Therapeutics, Inc. Filed by: Fairmount Funds Management LLC

Wed, 01 Jul 2026 21:30:00 -0400

si-local-file:///var/storage/secattach/20260701/26722785.html

Form 4 Oruka Therapeutics, Inc. For: Jul 01 Filed by: Fairmount Healthcare Fund II L.P.

Wed, 01 Jul 2026 21:30:00 -0400

si-local-file:///var/storage/secattach/20260701/26722786.html

Form 4 Oruka Therapeutics, Inc. For: Jul 01 Filed by: Fairmount Healthcare Fund II L.P.

Wed, 01 Jul 2026 21:30:00 -0400

si-local-file:///var/storage/secattach/20260701/26722786.html

Form 4 Oruka Therapeutics, Inc. For: Jul 01 Filed by: Sandler Laura Lee

Wed, 01 Jul 2026 19:58:00 -0400

si-local-file:///var/storage/secattach/20260701/26722633.html

Form 4 Oruka Therapeutics, Inc. For: Jul 01 Filed by: Sandler Laura Lee

Wed, 01 Jul 2026 19:58:00 -0400

si-local-file:///var/storage/secattach/20260701/26722633.html

Oruka Therapeutics (ORKA) PT Raised to $130 at UBS as Stock Undervalued

Wed, 01 Jul 2026 09:21:09 -0400

UBS analyst Michael Yee raised the price target on Oruka Therapeutics (NASDAQ: ORKA) to $130.00 (from $100.00) while maintaining a Buy rating.

The analyst commented, "We continue to like ORKA into the H2 28-week efficacy data readout and initial durability data. We believe the H2 data will likely show higher efficacy than the 16-week dataset and Skyrizi too at the same 28-week timepoint, supported by numerous psoriasis studies that generally demonstrate improving efficacy over time. While the stock has had a significant run-up, we still view it as undervalued at a ~$8-9B market cap* relative to comps including RXDX and APGE

Oruka Therapeutics (ORKA) PT Raised to $130 at UBS as Stock Undervalued

Wed, 01 Jul 2026 09:21:09 -0400

UBS analyst Michael Yee raised the price target on Oruka Therapeutics (NASDAQ: ORKA) to $130.00 (from $100.00) while maintaining a Buy rating.

H.C. Wainwright Reiterates Buy Rating on Oruka Therapeutics (ORKA)

Tue, 23 Jun 2026 06:49:23 -0400

H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Buy rating and $120.00 price target on Oruka Therapeutics (NASDAQ: ORKA).

The analyst commented: "Yesterday, AbbVie and Apogee Therapeutics announced that they have entered into a definitive agreement under which AbbVie will acquire Apogee and its diverse pipeline of multiple clinical-stage candidates in development across inflammatory and immunological diseases, including atopic dermatitis (AD) and asthma. The acquisition complements AbbVie's existing immunology portfolio and accelerates AbbVie's clinical presence in the respiratory space. Under the terms of the transaction, AbbVie will acquire all outstanding shares of Apogee for $135.11 per share in cash. The transaction

Form 4 Oruka Therapeutics, Inc. For: Jun 22 Filed by: Agarwal Arjun

Mon, 22 Jun 2026 20:00:00 -0400

si-local-file:///var/storage/secattach/20260622/26674543.html

Form 4 Oruka Therapeutics, Inc. For: Jun 22 Filed by: Agarwal Arjun

Mon, 22 Jun 2026 20:00:00 -0400

si-local-file:///var/storage/secattach/20260622/26674543.html

Form 4 Oruka Therapeutics, Inc. For: Jun 12 Filed by: Agarwal Arjun

Mon, 15 Jun 2026 18:57:00 -0400

si-local-file:///var/storage/secattach/20260615/26648962.html

Form 4 Oruka Therapeutics, Inc. For: Jun 12 Filed by: Agarwal Arjun

Mon, 15 Jun 2026 18:57:00 -0400

si-local-file:///var/storage/secattach/20260615/26648962.html

Form 4 Oruka Therapeutics, Inc. For: Jun 15 Filed by: Goncalves Joana

Mon, 15 Jun 2026 18:54:00 -0400

si-local-file:///var/storage/secattach/20260615/26648961.html

Form 4 Oruka Therapeutics, Inc. For: Jun 15 Filed by: Goncalves Joana

Mon, 15 Jun 2026 18:54:00 -0400

si-local-file:///var/storage/secattach/20260615/26648961.html